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Introduction: Pulmonary carcinoid tumors account for approxi-
mately 5% of all lung malignancies in adults, and comprise 30% of 
all carcinoid tumors. There are limited reagents available to study 
these rare tumors, and consequently no major advances have been 
made for patient treatment. We report the generation and charac-
terization of human pulmonary carcinoid tumor cell lines to study 
underlying biology, and to provide models for testing novel chemo-
therapeutic agents.
Methods: Tissue was harvested from three patients with primary 
pulmonary typical carcinoid tumors undergoing surgical resection. 
The tumor was dissociated and plated onto dishes in culture media. 
The established cell lines were characterized by immunohistochem-
istry, Western blotting, and cell proliferation assays. Tumorigenicity 
was confirmed by soft agar growth and the ability to form tumors in 
a mouse xenograft model. Exome and RNA sequencing of patient 
tumor samples and cell lines was performed using standard protocols.
Results: Three typical carcinoid tumor lines grew as adherent mono-
layers in vitro, expressed neuroendocrine markers consistent with 
the primary tumor, and formed colonies in soft agar. A single cell 
line produced lung tumors in nude mice after intravenous injection. 
Exome and RNA sequencing of this cell line showed lineage rela-
tionship with the primary tumor, and demonstrated mutations in a 
number of genes related to neuronal differentiation.
Conclusion: Three human pulmonary typical carcinoid tumor cell 
lines have been generated and characterized as a tool for studying the 
biology and novel treatment approaches for these rare tumors.
Key Words: Typical carcinoid, Neuroendocrine cells, Lung cancer; 
Atypical carcinoid, Exome sequencing, Cell line generation.
(J Thorac Oncol. 2014;9: 1763–1771)
Pulmonary carcinoid tumors represent a subset of up to 5% of all primary bronchopulmonary neoplasms.1,2 Their inci-
dence has rapidly increased within the past 30 years, and was 
1.57 per 100,000 in 20033. Overall, carcinoid tumors may be 
found elsewhere in the body, most commonly in the appen-
dix, followed by rectum, ileum, lungs, bronchi, and stomach.2 
Pulmonary carcinoid tumors are thought to arise from the neu-
roendocrine cells of the bronchopulmonary epithelium.4
The 2004 World Health Organization classification of 
lung tumors groups pulmonary neuroendocrine tumors into 
four main tumor types: low-grade typical carcinoid tumors 
(TC), intermediate-grade atypical carcinoid tumors (AC), 
high-grade large cell neuroendocrine carcinomas, and small-
cell lung cancers.5,6 Immunohistochemical and morphologic 
features are currently utilized to establish a diagnosis and to 
distinguish between typical and atypical carcinoid tumors.7 
Early stage typical carcinoid tumors are associated with a 
good prognosis after surgical resection, with a 5-year survival 
of ~88% versus ~50% for atypical carcinoid tumors.1
Complete surgical resection of the tumor with regional 
and mediastinal lymph node dissection currently remains the 
treatment of choice for cure in patients able to tolerate sur-
gery. In those patients with tumors not amenable to surgical 
resection or with systemic metastatic disease, chemotherapeu-
tic options have failed to succeed with low response rates of 
~20% or less.8–11 This suggest that an acceleration of preclini-
cal research to better understand the biology of these tumors 
is required to facilitate identification of novel targeted agents 
and improve chemotherapeutic options for advanced tumors.
Carcinoid cell line resources to study the biology of pul-
monary carcinoid tumors are currently very limited. Since the 
original description of four carcinoid cell lines by the NCI-
Navy Medical Oncology Branch cell line bank, NCI-H292 
has been reclassified as a mucoepidermoid pulmonary carci-
noma.12 NCI-H727, classified as a typical carcinoid tumor, is 
clinically inconsistent with the biology of a typical carcinoid 
tumor. It was derived from a stage 3A right upper lobe lung 
mass from a 65-year old white female, 60 pack-years smoker 
on April 24, 1984. She had chemotherapy and radiation ther-
apy and died 4 months later (August 19, 1984) from brain 
metastases.13 NCI-H727 grows as an adherent monolayer and 
harbors the G12V K-ras mutation. Given the highly unusual 
clinical outcome of this patient from which this cell line was 
derived and the presence of K-ras mutation, we believe that 
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NCI-H727 is likely a non–small-cell lung cancer (NSCLC) 
with neuroendocrine features instead of a typical carcinoid 
tumor. Up to 30% of NSCLC in patients who smoke harbor 
K-ras mutations, while we have found 0/31 K-ras mutations 
in 24 TC and 7 AC tumors tested to date.14 NCI-H720 is 
derived from a lung tumor (stage not reported) from a male 
(age and race not reported) and is a presumed atypical carci-
noid tumor.13 NCI-H720 grows as a cell suspension in HITES 
medium supplemented with 5% fetal bovine serum. NCI-
H835 is a presumed typical carcinoid tumor from a 48-year 
old black nonsmoking female and was established as float-
ing cells in ACL-4 medium.13 Patient treatment and follow-up 
was not reported for either of NCI-H720 or NCI-H835. The 
currently available cell lines unfortunately lack detailed clini-
cal and histologic information. This may explain why a small 
number of in vitro studies have failed so far in translating to 
clinical application.15 For these reasons, this study aimed to 
create cell lines as necessary research resources for advanc-
ing understanding of the biology and treatment response of 
pulmonary carcinoid tumors. These resources will provide the 
foundation for functionally dissecting cancer pathways and 
testing novel targeted agents for improved therapies.
MATERIALS AND METHODS
Establishment of Cell Lines
The Mayo Clinic College of Medicine Institutional 
Review Board approved this study. Three patients scheduled 
for resection of suspected primary bronchopulmonary carci-
noid tumors were consented for cell line generation. Tumors 
were reviewed and confirmed based on the 2004 WHO clas-
sification by a lung pathologist experienced in the assessment 
of neuroendocrine lung cancers. Tissue from the resected 
typical carcinoid tumors harvested at the time of surgery was 
dissected from surrounding tissue and mechanically homog-
enized into a cell suspension. Cells were filtered through a 
100 micron filter to disperse individual tumor cells and cen-
trifuged twice at 1000 rpm for 10 minutes to remove debris. 
Cells were plated in RPMI 1640 + 10% FBS or DMEM + 10% 
FBS medium and incubated at 37°C and 5% CO
2
 with daily 
examination of the plates. Medium was changed every 2–7 
days based on observation of the cells and progression of the 
culture. Cells were passaged using trypsin dispersion when 
the plates became 75% or more confluent.
Immunohistochemistry
Carcinoid cell lines were examined for expression of 
neuroendocrine markers synaptophysin (SYP) and chromo-
granin A (CGA). After cytospin of 75,000 cells in 100 µl of 
medium onto a charged slide for 6 minutes at 600 rpm, the 
slides were air-dried for 4 hours at room temperature and ace-
tone-fixed for 20 min at -20°C before blocking for 2 hours at 
4°C with 10% horse serum. Thereafter the slides were incu-
bated for 2 hours at 4°C with anti-SYP 1:1000 (rabbit) and 
anti-CGA 1:100 (mouse) in PBS + 0.2% Triton x-100. After 
washing the slides they were incubated at room temperature 
for 30 minutes in the dark with 1:200 dilution of anti-mouse 
rhodamine. Incubation followed for 30 minutes in the dark 
with 1:1000 dilution of anti-rabbit FITC after washing the 
slides again. After removal of the salts, the air-dried slides 
were stained with DAPI and covered.
The resected tumor specimens were stained with hema-
toxylin and eosin (H&E), SYP, and CGA. The stained sections 
were then photographed.
Western Blotting
Carcinoid cells were harvested with lysis buffer con-
taining 1% Nonidet 40, 150 mM NaCl, 50 mM HEPES, 2m 
MEDTA, 3 mM EGTA, and 50 mM β-glycerophosphate with 
protease inhibitors pepstatin, leupeptin, aprotinin (10 µg/
ml), PMSF (2 mM), and NaF (50 mM). Protein concentration 
was measured using the BCA protein assay reagent (Pierce 
Biotechnology, Rockford, IL). 100 µg of each protein lysate 
was separated on a long 10% SDS-PAGE gel for 16 hours at 
120 volts and transferred to PDVF membrane. Nonspecific sites 
were blocked with TTBS containing 5% milk before addition of 
the primary antibodies. Primary antibody for CGA (Chemicon, 
Billerica, MA) was used at 1:500 dilution, followed by applica-
tion of secondary antibody antimouse HRP conjugate (1:1000) 
dilution. Bound antibodies were detected with enhanced chemi-
luminescence (Amersham Bioscience, Piscataway, NJ).
Cell Proliferation
The CyQUANT NF assay is based on measurement of 
cellular DNA content via fluorescent dye binding. Because 
cellular DNA content is highly regulated, it is closely propor-
tional to the cell number. The CyQuant NF protocol requires 
aspiration of growth medium (for adherent cells), replace-
ment with dye binding solution, incubation for 30–60 min-
utes, and then measurement of fluorescence in a microplate 
reader. Cells were plated in quadruplicate in a 96-well micro-
plate at a density of 5000 cells per well. At various time points 
the growth medium was removed and washed with 1× PBS. 
100 µl of 1× dye binding solution prepared according to pro-
tocol (Invitrogen Grand Island, NY) was aliquoted into each 
microplate well. The covered microplate was incubated at 
37°C for 60 minutes. This incubation period is required for 
equilibration of dye–DNA binding, resulting in a stable fluo-
rescent endpoint. The fluorescence intensity was measured 
using a Fluoroskan Ascent fluorescence microplate reader 
(Thermo Scientific, Waltham, MA) with excitation at 485 nm 
and emission detection at 538 nm.
Soft Agar Assays for Colony Formation
Six-well plates were layered with media containing 
0.8% agar to create a bottom layer. The fluorescence intensity 
was measured using a Fluoroskan Ascent fluorescence micro-
plate reader (Thermo Scientific) with excitation at 485 nm and 
emission detection at 538 nm. Visible colonies greater than 
50 microns were counted by light microscopy. All conditions 
were performed in triplicate.
Mouse Xenograft Model
Study approval was obtained from the Mayo Clinic 
Institutional Animal Care and Use Committee (IACUC). 
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Male nude mice which were 4- to 6-week old (Nomenclature: 
Crl:NU-Foxn1nu) were purchased from Charles River 
Laboratories International, Inc. (Wilmington, MA) and housed 
according to the standard IACUC guidelines. Approximately, 
2 × 106 cells suspended in 100 μl PBS + 100 μl Matrigel (BD 
Biosciences, San Jose, CA) were injected subcutaneously 
into the left flank of the nude mice, and thereafter observed 
daily for tumor growth and assessment of tumor volumes. 
Intravenous injections of carcinoid cell lines were performed 
as follows: the mice were anesthetized with 10μl xylazine/x 
per 1 g bodyweight and their necks were prepped with povi-
done-iodine solution (Novaplus, Irving, TX). An 8-mm inci-
sion was made over the right jugular vein and after blunt 
dissection of the subcutaneous tissue, and the internal jugu-
lar vein exposed. We then injected 1 × 106 cells suspended in 
100 μl PBS slowly over 2–3 minutes with a 25 gauge needle 
into the internal jugular vein. Upon completion, hemostasis 
was ensured by compression of the puncture site before clos-
ing the skin with veterinary Nexaband liquid topical tissue 
adhesive (Abbott Laboratories, Abbott Park, IL). The animals 
were euthanized with CO
2
 insufflation at various time points. 
The xenograft tumor tissues were formalin fixed and paraffin 
embedded, and 5 μm sections were stained with H&E.
Exome and RNA Sequencing
Genomic DNA was extracted from fresh frozen tissue 
using the DNAeasy blood and tissue kit (Qiagen, Valencia, 
CA). Whole exome sequencing was performed by Otogenetics 
corporation using the Agilent V4 (51Mbp) exome enrichment 
and paired-end sample preparation kit. Enriched samples 
were sequenced on an Illumina Hiseq 2000 instrument to 
greater than 30× coverage using paired-end technology. Total 
RNA from frozen tissues were extracted using a trizol-based 
method and the RNAeasy mini kit (Qiagen). RNA sequenc-
ing was also performed by Otogenetics using a poly-A-based 
cDNA preparation protocol. Double stranded cDNA was frag-
mented, used for Illumina library preparation and sequenced 
on the Hiseq 2000 to generate 20M reads.
Sequencing Data Analysis
The filtered reads were aligned against the human refer-
ence genome (hg19) using Bowtie2. Samtools was then used 
to remove PCR duplicates and for SNP and short INDEL call-
ing in the exomic region. A ratio of the read depth and the 
Phred Scaled Quality was calculated between the variant and 
reference alleles. The genomic variant file was then uploaded 
into the ingenuity variant analysis package for tertiary analy-
sis. Cancer-relevant variants were identified according to the 
following filtering criteria: (1) common variant filtering to 
remove common variants present in the 1000 genome project, 
the Complete Genomic public genomes and the NHLBI ESP 
exomes projects; (2) predicted deleterious filtering to keep 
variants in cases experimentally observed to be pathogenic, 
possible pathogenic, or associated with gain in the literature 
or predicted to be loss of function; (3) genetic analysis filter-
ing to keep variants in cases associated with gain of function 
or are homozygous, compound heterozygous, haploinsuffi-
cient, hemizygous, and nullizygous in at least one case and to 
remove same found in all controls; (4) Cancer driver variant 
filtering to keep variants that are found in cancer-associated 
mouse knockouts, cellular processes and pathways, cancer 
therapeutic targets, in published cancer literature, and found 
in the COSMIC and TCGA database at a frequency of 0.01; 
(5) confidence filtering to keep variants with call quality of at 
least 50 and read depth of at least 20. Manual reanalysis of all 
variants in all cases after filtering was performed to remove 
variants found in repetitive genomic regions.
RNA-seq analysis was performed using the Partek Flow 
and Genomic Suite. RNA sequence reads were first aligned 
to human genome sequence (HG19) and then mapped to the 
transcriptome to estimate transcript abundance. Detection of 
SNVs and indels was carried out using samtools mpileup and 
bcftools for calling consensus. Fusion genes were detected 
using the paired-end reads. Differential gene expression in 
tumors and cell lines using surrounding tissue as a reference 
was determined using Partek Genomic suite and cross-refer-
enced with significantly mutated genes in the Ingenuity vari-
ant analysis package.
Validation of Sequencing Results
SNV and small indel mutations in biologically relevant 
genes were validated using targeted sequencing. Briefly, prim-
ers flanking regions of mutation were designed to generate 
PCR amplicons. Libraries of tagged amplicons were prepared 
using the Nextera DNA sample prep kit (Illumina, San Diego, 
CA) and sequenced using an Illumina Hiseq sequencer.
RESULTS
Characterization of Pulmonary 
Typical Carcinoid Cell Lines
We surgically resected typical carcinoid tumors from 
three stage I patients, two of whom were prior smokers, and 
the third a never smoker. Clinical characteristics of the patients 
are described in Table 1. Pulmonary carcinoid tumors express 
various neuroendocrine markers. To confirm that the original 
resected tumors were carcinoid tumors, we stained for expres-
sion of the neuroendocrine markers CGA and SYP. The results 
showed that TC1, TC2, and TC3 tumors showed positive stain-
ing for both neuroendocrine markers (Fig. 1). We then estab-
lished one cell line from each patient and labeled them TC1, 
TC2, and TC3. To verify that the generated cell lines were 
indeed representative of the resected carcinoid tumor, we per-
formed immunohistochemistry using PC12 as a positive con-
trol (Fig. 2A) and immunoblotting staining (Fig. 2B) for SYP 
and CGA expression. The results showed varying levels of 
CGA and SYP expression in both the resected tumors and the 
established cell lines, suggesting that the established cell lines 
possess characteristics of neuroendocrine differentiation.
Growth Rate of TC Carcinoid Cell Lines
Pulmonary typical carcinoid tumors are mostly small 
in size and grow at a much slower rate compared to more 
aggressive cancers like lung adenocarcinoma.16 To deter-
mine the growth rate of our carcinoid cell lines, we per-
formed cell proliferation assays. All cells were continuously 
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passaged and all experiments utilized cells from passage 
numbers 8 to 12. All three cell lines grow as adherent mono-
layers in cell culture and require serum for proliferation 
(Fig. 3A–C). In the absence of serum, growth of all three 
lines cease. We calculated the doubling times for these cell 
lines as 11.52 days for TC1, 8.05 days for TC2, and 9.33 
days for TC3 (Fig. 3D).17
Colony Formation in Soft Agar
To characterize the tumorigenic potential of the pul-
monary carcinoid tumor cell lines, we examined the abil-
ity of TC1, TC2, and TC3 to form colonies in soft agar, a 
tumorigenic characteristic of anchorage-independent growth. 
Compared to the human non–small-cell lung carcinoma cell 
line A549 (which grew 1250 colonies >50 microns) and the 
normal human bronchial epithelial cell line NHBE (which 
failed to generate colonies), the TC1, TC2, and TC3 cell lines 
formed 372, 139, and 86 colonies >50 microns, respectively 
(Fig. 4). The reduced colony-forming capacity of the cells 
lines, in addition to their low proliferative rate, is consistent 
with the less aggressive yet still malignant biology of carci-
noid tumors.
Xenograft Formation in Nude Mice
To further assess the tumor-forming ability of the cell 
lines, cells were injected subcutaneously into nude mice for 
xenograft tumor formation and observed for 25 weeks. No 
tumor formation was detected in any of the mice with subcuta-
neous injection. Cells were then injected intravenously which 
generated xenograft tumors in nude mice only for cell line TC3. 
As illustrated in Figure 4, the lung xenograft tumors generated 
from cell line TC3 have typical carcinoid tumor histology (Fig. 
5A) and resemble the original patient tumor (Fig. 5B), suggest-
ing that the TC3 cell line in particular adequately and accu-
rately represents a pulmonary carcinoid tumor and is similar in 
histologic characteristics to the original tumor.
Exome and RNA Sequencing of a Primary 
Carcinoid Tumor and Derived Cell Line (TC3)
We used a genomic approach and performed molecular 
analysis using whole exome and RNA sequencing of the pri-
mary tumor, surrounding histologically normal lung, and the 
TC3 cell line to determine whether the TC3 cell line truly rep-
resents the genomic alterations present in the primary tumor. 
We chose TC3 for sequencing based on the fact it was the 
TABLE 1.  Patient Characteristics of Derived Cell Lines
TC1 TC2 TC3
Age (yr) 40 71 27
Sex M F M
Surgery date May 30, 2008 November 3, 2008 August 4, 2008
Histology TC TC TC
Location RLL LLL LLL
Procedure Lobectomy Lobectomy Lobectomy
Stage T2N0M0 T1N0M0 T2N0M0
Smoking Prior 20 p-y Prior < 3 p-y Never smoked
Cell line properties Adherent monolayer Adherent monolayer Adherent monolayer
Medium RPMI1640 + 10% FBS RPMI1640 + 10% FBS DMEM + 10% FBS
FIGURE 1.  Histological staining of carcinoid 
tumors. Photomicrograph of H&E, CGA, and SYP 
staining of carcinoid tumors used for establishing 
TC1, TC2, and TC3 cell lines.
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only cell line to form xenograft tumors in nude mice. DNA 
and RNA were purified from the tumor, associated normal 
lung, and the derived cell line to generate libraries for next 
generation sequencing. The distribution of different varia-
tion types and the associated translation impact between the 
tumor and the derived cell line is shown in Tables 2 and 3. 
To identify potential driver mutations, we applied a biologi-
cally relevant filter to focus on alterations in genes known to 
impact neuronal or neuroendocrine biology using the ingenu-
ity variant analysis tool, and validated these mutations using 
PCR and targeted sequencing. We identified 14 alterations 
in genes with a role in neuronal or neuroendocrine biology 
that were common between the tumor and derived cell line 
(Fig. 6). Thirty-two mutations were found only in the primary 
tumor, while 20 variants occurred exclusively in the cell line. 
RNA-seq analyses also showed a corresponding decrease in 
the expression levels of four of the mutant genes, EP400, 
LSR, SRD5A2, and MEOX2 (not shown). Neuroendocrine-
relevant variants included mutations in ACVR2A, MUC2, 
BCLAF1, SEMA3B, RETNLB, MUC4, NOP16, PODXL, 
DCP1B, EP400, and HRC (Table 4). Analysis of SNVs found 
in the RNA-sequencing data included mutations in TIMM13, 
MYADML, DNAH1, TSLP, NOP16, PPIL1, and GCLC. A 
mutation in NOP16 was found by both whole exome and RNA-
sequencing analysis. NOP16 is regulated by both MYC and 
estrogens, and high NOP16 expression levels have been cor-
related with poor clinical outcome in breast cancer patients.18 
We also performed similarity testing based on the total number 
of mutations identified, and were able to demonstrate a closer 
relationship of the cell line to carcinoid tumor tissue than to 
surrounding normal lung (not shown). This was also the case 
when assessing only loci that had acquired a de novo mutation 
as part of lineage analysis. Overall, these molecular analyses 
confirmed that the TC3 cell line and the parental tumor con-
tain a number of common cancer-associated variants, infer-
ring that the cell line is a true representation of a subset of the 
genomic alterations present in the primary tumor.
DISCUSSION
The standard treatment approach to early stage pulmo-
nary carcinoid tumors is surgical resection, as this currently 
provides the best chance for cure. In some patients, the ana-
tomic location or metastatic spread of the tumor may preclude 
surgical resection, therefore requiring alternative treatments. 
Somatostatin analogues and cytotoxic chemotherapy are the 
current mainstays of medical treatment. The role of soma-
tostatin analogues is mainly for symptomatic palliation rather 
than for therapeutic tumor intervention.19 With respect to che-
motherapy, a combination of 5-flurouracil, cisplatin and strep-
tozocin, or etoposide and platinum-based regimens have been 
used as first line treatment.20 Other reported regimens include 
FDE (5-FU, dacarbazine, and epirubicin) with a reported 
response rate of 27.8% and disease stabilization greater than 6 
FIGURE 2.  Expression of neuroendocrine markers. 
A, Immunohistochemistry staining demonstrating 
expression of CGA (red) and SYP (green) in carci-
noid cell lines. B, Western blot demonstrating CGA 
(75 kDa) and SYP (43 kDa) expression in the estab-
lished cell lines TC1, TC2, and TC3.
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months in 45.8% of patients, and single agent temozolomide, 
used in 36 patients with metastatic neuroendocrine tumors 
(of which 13 were lung carcinoids), where 31% had a partial 
remission and 31% had stable disease.21,22
A recent immunohistochemical analysis of EGFR, ErbB2, 
ErbB3, and ErbB4 expression in 24 typical and seven atypical 
carcinoid tumors showed that 45.8% of the typical and 28.6% 
of the atypical carcinoid tumors express EGFR.14 These findings 
suggest that there might be potential clinical use of EGFR inhibi-
tors in patients with EGFR-positive unresectable pulmonary 
carcinoid tumors, despite the absence of sensitizing EGFR muta-
tions. With our established carcinoid tumor cell lines there is a 
unique opportunity to develop studies to verify these findings and 
investigate the potential use of novel chemotherapeutic agents.
The use of mouse xenografts to grow human tumors 
to perform preclinical drug testing has yielded useful 
FIGURE 3.  Typical carcinoid tumor cell lines in vitro growth characteristics. TC1, TC2, and TC3 cells were grown in vitro with 
or without 10% serum and proliferation was measured at various time points. Data shown is the mean fluorescence from the 
proliferation assay of triplicate samples +/- SEM.
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information for many compounds which have gone forward 
to phase I clinical trials. This approach, however, is not appli-
cable for all tumor cell lines. Certain tumor cell lines do not 
form xenografts, or form tumors which have significant tumor 
size variation within the same xenograft tumor groups, which 
may limit the usefulness of this model system. In this study, 
although we applied similar xenograft generation techniques 
utilized in our laboratory for other cell types and as reported 
in the literature, we were not been able to generate xenograft 
tumors from subcutaneous injection of the human typical 
carcinoid cell lines.23 Using intrajugular intravenous injec-
tions, we were successful with 1 of 3 carcinoid cell lines in 
establishing pulmonary tumors with the cell line TC3. This 
success rate of 33% is consistent with that reported in the lit-
erature for a number of cell types. Furthermore, not all tumors 
FIGURE 4.  Colony formation of lung carcinoid tumor cells in 
soft agar. TC1, TC2, and TC3 cells were plated in triplicate with 
control NSCLC A549 cells and nonneoplastic normal human 
bronchial epithelial cells (NHBEC) in soft agar. After 2 weeks 
of culture colonies greater than 50 microns in diameter were 
counted. Data shown is the mean of triplicate plates +/- SEM.
FIGURE 5.  Pulmonary carcinoid xenograft tumor. A, Gross 
lung specimen from xenograft mouse showing large tumor 
nodule (arrow). B, Xenograft tumor (H&E, 10× and 40×) with 
comparison to the original patient tumor (H&E, 10× and 40×) 
demonstrating typical neuroendocrine features in both samples.
TABLE 2.  Distribution of Types of Genomic Alterations in 
Primary Carcinoid Tumor and TC3 Cell Line
Variation Type Tumor Cell Line
Complex 3 3
Deletion 30 27
Insertion 43 37
Substitution 292 298
Total 368 365
TABLE 3.  Translational Impact of Genomic Alterations in 
Primary Carcinoid Tumor and TC3 Cell Line
Translational Impact Tumor Cell Line
Frameshift 76 67
In-frame 220 226
Missense 62 62
Stop gain 1 2
Unknown 9 8
Total 368 365
FIGURE 6.  Venn diagram showing common and distinct 
mutations in the TC3 tumor and cell line.
TABLE 4.  Genomic properties of putative cancer driver vari-
ants found in both primary tumor and TC3 cell line
Gene Symbol Protein Variant Translation Impact
EP400 2741_2742insQ In-frame
DCP1B 253_254insQ In-frame
KCNJ12 A185V Missense
LSR 500_501insR In-frame
PDE11A 563_564insS In-frame
SRD5A2 S31fs* Frameshift
RETNLB L14fs* Frameshift
CLDN16 A56fs* Frameshift
MUC4 113_114insVTQET In-frame
WWC1 865delE In-frame
MEOX2 71delH In-frame
MUC2 S1459T Missense
NOP16 R195fs*; R196fs* Frameshift
DCP1B 253_254insQ In-frame
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form xenografts, even those with relatively aggressive biol-
ogy, for reasons which are unclear. Fichtner and colleagues 
transplanted 102 NSCLCs into immunodeficient mice, yet 
only generated 25 xenografts for a success rate of 24.5%. This 
engraftment rate of human lung cancer xenografts is similar to 
that reported by Cutz et al. and Perez-Soler et al.24,25
We also exploited next generation sequencing tech-
nology to authenticate and assess the degree of similarity 
between the TC3 cell line and the parent primary tumor it 
was derived from. As part of this analysis, we also identified 
a number of mutations not previously described in pulmonary 
carcinoid tumors. We identified and validated 14 mutations in 
biologically relevant genes with links to neuroendocrine func-
tion that were present in both the tumor and cell line (Fig. 5). 
Although the biological impact of the majority of these muta-
tions is yet to be determined, they provide an opportunity for 
the development of targeted therapeutics for a disease where 
currently there are none available. Biologically relevant vari-
ants included mutations in genes such as ACVR2A, MUC2, 
BCLAF1, SEMA3B, RETNLB, MUC4, NOP16, PODXL, 
DCP1B, EP400, and HRC. A missense mutant in ACVR2A 
gene (p.K315N) has been associated with oligodendroglioma 
in human brain.26 MUC2 may play a role in tumorigenesis 
through regulation of the MLH1 gene, while BCLAF1 acts 
through regulation of PRKCD and TP53 genes.27 A decrease 
in MUC gene expression by siRNA resulted in increased 
binding of the ERBB2 receptor to Trastuzumab.28 NOP16 is 
overexpressed in breast cancer cells and correlates with poor 
patient outcome. It also may play a role in neuroendocrine 
neoplasia through binding to COPS5.29 PODXL regulates 
pancreatic cancer by acting upstream of CDH1, MMP9, and 
VIM while DCP1B regulates SMAD4 in colorectal can-
cers.30–34 EP400 and HRC both play a role in tumorigenesis 
by regulating CDKN1A, TP53, and KIAA0101 in IMR90 and 
mouse embryonic fibroblast cell lines as well as pancreatic 
neuroendocrine tumors.35–39 Analysis of SNVs found in the 
RNA-sequencing data include mutations in ovarian, cervi-
cal, breast, colon, and lung cancer genes such as MYADML, 
NOP16, PPIL1, and GCLC.40–44
During the preparation of this manuscript, Fernandez-
Cuesta et al. published an integrated analysis of gene copy 
number (n = 54), genome/exome (n = 44), and transcriptome 
(n = 69) sequencing of pulmonary carcinoids. They found 
mutations in chromatin-remodelling genes and in particu-
lar histone modifiers and subunits of the SWI/SNF complex 
such as MEN1, PSIP1, and ARID1A in 22% of the cases 
sequenced.45 We did not find any mutations in components of 
this pathway in our data. This may be due to the low overall 
mutation rate in pulmonary carcinoids, where recurrent muta-
tions in individual or sets of genes may be difficult to detect 
in small sample sets. It is also worthy of note that the majority 
of samples analyzed by Fernandez-Cuesta et al. did not harbor 
any mutations in chromatin-remodelling genes and may be 
driven by other unknown pathways.
In summary, we have successfully generated three pul-
monary typical carcinoid cell lines for studies in the biol-
ogy of carcinoid tumors and the in vitro testing of novel 
therapeutic agents. These cell lines are freely available for 
distribution to the research community to accelerate research 
for novel therapies in this understudied tumor. These cell 
lines grew as adherent monolayers in vitro, expressed neu-
roendocrine markers consistent with the primary tumor, and 
formed colonies in soft agar. A single cell line produced lung 
tumors in nude mice after intravenous injection. Exome and 
RNA sequencing of this cell line showed lineage relation-
ship with the primary tumor, and demonstrated mutations in 
a number of genes related to neuronal differentiation. These 
cell lines offer an opportunity to advance the understanding 
of carcinoid tumor biology and to improve patient treatments 
for this disease.
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